Lantern Pharma Inc   (LTRN)
Other Ticker:  
Price: $4.8100 $-0.29 -5.686%
Day's High: $5.64 Week Perf: 23.02 %
Day's Low: $ 4.62 30 Day Perf: 17.6 %
Volume (M): 716 52 Wk High: $ 6.18
Volume (M$): $ 3,445 52 Wk Avg: $4.40
Open: $5.51 52 Wk Low: $2.38

 Market Capitalization (Millions $) 52
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Lantern Pharma Inc
Lantern Pharma Inc is a biotechnology company that focuses on using artificial intelligence (AI) and machine learning (ML) in drug discovery and development. The company aims to improve the efficacy and success rate of cancer therapeutics by identifying novel biomarkers and repurposing existing FDA-approved drugs. Lantern Pharma's AI-driven platform helps to predict patient response to specific cancer treatments and enables precision medicine approaches. By leveraging big data analytics, Lantern Pharma aims to accelerate the identification and development of personalized therapies for cancer patients, ultimately leading to better patient outcomes.

   Company Address: 1920 McKinney Avenue Dallas 75201 TX
   Company Phone Number: 277-1136   Stock Exchange / Ticker: NASDAQ LTRN
   LTRN is expected to report next financial results on March 19, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Lantern Pharma Inc

Lantern Pharma Inc continues to face financial challenges as expenditures spike in Q2 2023, reporting an operating loss of $-5.19 million

Lantern Pharma Inc, a company in the Major Pharmaceutical Preparations industry, recently announced its second-quarter earnings for 2023. Unfortunately, the company reported an operating loss of $-5.190297 million, which is a decline from the $-4.394821 million loss in the same quarter of the previous year.
Analysts are now speculating on when Lantern Pharma Inc will be able to generate positive revenue. The company is implementing various corporate policies in an effort to ensure a consistent business performance. This is particularly important considering the growing deficit faced by the company, which has increased from $-4.492 million in the second quarter of 2022 to $-4.746 million in the present period.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com